CTXR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

4.500

-446.15%

4.500

-454.33%

4.750

-693.75%

Estimates Revision

The market is revising No Change the revenue expectations for Citius Pharmaceuticals, Inc. (CTXR) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -27.83%.

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2026

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-27.83%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Citius Pharmaceuticals Inc (CTXR.O) is 0.45, compared to its 5-year average forward P/E of -5.03. For a more detailed relative valuation and DCF analysis to assess Citius Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.03

Current PE

0.45

Overvalued PE

12.55

Undervalued PE

-22.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.37

Current PS

0.28

Overvalued PS

10.23

Undervalued PS

-1.49

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CTXR News & Events

Events Timeline

No data

News

8.5

2025-12-27Yahoo Finance

UiPath to Join S&P Midcap 400 Index Effective January 2, 2026

4.5

2025-12-24Benzinga

U.S. Stocks Rise with Dow Jones Surging Over 200 Points

4.5

2025-12-24Benzinga

U.S. Initial Jobless Claims Drop to 214,000, Beating Estimates

People Also Watch

Frequently Asked Questions

What is Citius Pharmaceuticals Inc (CTXR) stock price today?

The current price of CTXR is 0.8877 USD — it has decreased -1.33 % in the last trading day.

What is Citius Pharmaceuticals Inc (CTXR)'s business?

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

What is the price predicton of CTXR Stock?

Wall Street analysts forecast CTXR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTXR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Citius Pharmaceuticals Inc (CTXR)'s revenue for the last quarter?

Citius Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Citius Pharmaceuticals Inc (CTXR)'s earnings per share (EPS) for the last quarter?

Citius Pharmaceuticals Inc. EPS for the last quarter amounts to -0.46 USD, decreased -71.07 % YoY.

What changes have occurred in the market's expectations for Citius Pharmaceuticals Inc (CTXR)'s fundamentals?

How many employees does Citius Pharmaceuticals Inc (CTXR). have?

Citius Pharmaceuticals Inc (CTXR) has 23 emplpoyees as of January 10 2026.

What is Citius Pharmaceuticals Inc (CTXR) market cap?

Today CTXR has the market capitalization of 18.43M USD.